Safety profile of the respiratory fluoroquinolone moxifloxacin: Comparison with other fluoroquinolones and other antibacterial classes

Drug Safety

Volumn 32, Issue 5, 2009, Pages 359-378

  Van Bambeke, Françoise ^a,b   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UCL7370 ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CEFIXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE SINUSITIS; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CARDIOTOXICITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFUSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; MALAISE; METABOLIC DISORDER; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUROTOXICITY; PALLOR; PHOTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PUSTULOSIS; QT INTERVAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TENDOM RUPTURE; TENDON RUPTURE; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VERTIGO;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; HUMANS; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 65949098180     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932050-00001     Document Type: Review

References (170)

1. US Levaquin® package insert [online]. Available fromURL: http://www.levaquin.com/levaquin/shared/pi/levaquin.pdf [Accessed 2009 Mar 18]
2. US Avelox® package insert [online]. Available from URL: http://www.univgraph.com/bayer/inserts/avelox.pdf [Accessed 2009 Mar 18]
3. Van Bambeke F, Michot JM, Van Eldere J. et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005 Apr; 11 (4): 256-80
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007 Mar 1; 44 Suppl. 2: S27-72
5. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005 Dec; 26 (6): 1138-80
6. Van Bambeke F, Reinert RR, Appelbaum PC, et al. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.Drugs 2007; 67 (16): 2355-82
7. Adam HJ, Schurek KN, Nichol KA, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007 Jan; 51 (1): 198-207
8. Volonakis K, Souli M, Kapaskelis A, et al. Evolution of resistance patterns and identification of risk factors for Streptococcus pneumoniae colonisation in daycare centre attendees in Athens, Greece. Int J Antimicrob Agents 2006 Oct; 28 (4): 297-301
9. Sill ML, Law DK, Zhou J, et al. Population genetics and antibiotic susceptibility of invasive Haemophilus influenzae in Manitoba, Canada, from 2000 to 2006. FEMS Immunol Med Microbiol 2007 Nov; 51 (2): 270-6
10. Fluit AC, Florijn A, Verhoef J, et al. Susceptibility of European beta-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003. J Antimicrob Chemother 2005 Jul; 56 (1): 133-8
11. Shin JH, Jung HJ, Kim HR, et al. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrob Agents Chemother 2007 Jul; 51 (7): 2625-7
12. Johnson DM, Stilwell MG, Fritsche TR, et al. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006 Sep; 56 (1): 69-74
13. Schurek KN, Adam HJ, Siemens CG, et al. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J Antimicrob Chemother 2005 Oct; 56 (4): 769-72
14. Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004 Nov; 24 (5): 479-84
15. Conte Jr JE, Golden JA, McIver M, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 2006 Aug; 28 (2): 114-21
16. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005 Jun; 33 (3): 106-14
17. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65 (7): 949-91
18. Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005 Feb; 6 (2): 283-93
19. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004 Jul; 26 (7): 940-50
20. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28 (5): 443-52
21. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.Drugs 2000 Jan; 59 (1): 115-39
22. Elies W, Landen H, Stauch K. Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice: results of a post-marketing surveillance study. Clin Drug Investig 2004; 24 (8): 431-9
23. Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008 Mar 25; 178 (7): 845-54
24. Arrieta JR, Galgano AS, Sakano E, et al. Moxifloxacin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 2007 Mar; 28 (2): 78-82
25. Chen W, Wu C, Li Z, et al. Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: results of a post-marketing surveillance study. Clin Drug Investig 2006; 26 (9): 501-9
26. Mittmann N, Jivarj F, Wong A, et al. Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis. Can J Infect Dis 2002 Sep; 13 (5): 293-300
27. Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004 May; 38 (5): 749-54
28. Klossek JM, Siegert R, Nikolaidis P, et al. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol 2003 Jan; 117 (1): 43-51
29. Ferguson BJ, Guzzetta RV, Spector SL, et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004 Sep; 131 (3): 207-14
30. Koch H, Landen H, Stauch K. Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin Drug Investig 2004; 24 (8): 449-55
31. Schaberg T, Moller M, File T, et al. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin Drug Investig 2006; 26 (12): 733-44
32. Zervos M, Martinez FJ, Amsden GW, et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007 Jan; 29 (1): 56-61
33. Urueta-Robledo J, Ariza H, Jardim JR, et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med 2006 Sep; 100 (9): 1504-11
34. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004 Feb; 23 (2): 129-37
35. Grassi C, Casali L, Curti E, et al. Efficacy and safety of short course (5-day) moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002 Dec; 14 (6): 597-608
36. Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001 Jul; 29 (4): 314-28
37. Lorenz J, Thate-Waschke IM, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001 Mar; 29 (2): 74-86
38. Barth J, Stauch K, Landen H. Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice. Clin Drug Investig 2005; 25 (11): 691-700
39. Koch H, Landen H, Stauch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients. Clin Drug Investig 2004; 24 (8): 441-8
40. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006 Jan 1; 42 (1): 73-81
41. Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin versus levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005 Nov; 128 (5): 3398-406
42. Vyas H, Krishnaswamy G. Images in clinical medicine: quinolone-associated rupture of the Achilles' tendon. N Engl J Med 2007 Nov 15; 357 (20): 2067
43. Hoeffken G, Talan D, Larsen LS, et al. Efficacy and safety of sequential moxifloxacin for treatment of communityacquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 2004 Oct; 23 (10): 772-5
44. Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of communityacquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004 Nov; 27 (4): 395-405
45. Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005 Jun; 24 (6): 367-76
46. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002 Jun; 46 (6): 1746-54
47. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in communityacquired pneumonia. Eur Respir J 2003 Jan; 21 (1): 135-43
48. Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of communityacquired pneumonia. Respir Med 2001 Jul; 95 (7): 553-64
49. Hoffken G, Barth J, Rubinstein E, et al. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection 2007 Dec; 35 (6): 414-20
50. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Drug Saf 2003; 26 (2): 109-20
51. Van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003 Aug 11; 163 (15): 1801-7
52. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995 Dec 14; 333 (24): 1600-7
53. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006 Mar 30; 354 (13): 1352-61
54. Motola D, Vargiu A, Leone R, et al. Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol 2007 Jan; 63 (1): 73-9
55. Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007; 30 (8): 697-703
56. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007 Nov; 41 (11): 1859-66
57. Simonin MA, Gegout-Pottie P, Minn A, et al. Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice. Antimicrob Agents Chemother 1999 Dec; 43 (12): 2915-21
58. Corps AN, Harrall RL, Curry VA, et al. Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford) 2005 Dec; 44 (12): 1514-7
59. Stahlmann R, Forster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother 1995 Sep; 39 (9): 2013-8
60. Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009 Mar; 33 (3): 194-200
61. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003 Jun 1; 36 (11): 1404-10
62. Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005 Mar; 4 (2): 299-309
63. Butler MW, Griffin JF, Quinlan WR, et al. Quinoloneassociated tendonitis: a potential problem in COPD? Ir J Med Sci 2001 Jul; 170 (3): 198-9
64. Burkhardt O, Kohnlein T, Pap T, et al. Recurrent tendinitis after treatment with two different fluoroquinolones. Scand J Infect Dis 2004; 36 (4): 315-6
65. Iannini PB. Fluoroquinolone toxicity: a review of classand agent-specific adverse effects. Drug Benefit Trends 2004; Suppl.: 34-41
66. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004 Mar; 125 (3): 953-64
67. Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007 Jul; 60 (1): 121-6
68. Iannini P, Mandell L, Felmingham J, et al. Adverse cutaneous reactions and drugs: a focus on antimicrobials. J Chemother 2006 Apr; 18 (2): 127-39
69. Nori S, Nebesio C, Brashear R, et al. Moxifloxacinassociated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. Arch Dermatol 2004 Dec; 140 (12): 1537-8
70. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)- results of a multinational case-control study (Euro- SCAR). Br J Dermatol 2007 Nov; 157 (5): 989-96
71. Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf 2007; 30 (8): 705-13
72. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. Curr Med Chem 2001 Mar; 8 (4): 371-84
73. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005 Jul 15; 41 Suppl. 2: S144-57
74. US Cipro- package insert [online]. Available from URL: http://www.univgraph.com/bayer/inserts/ciprotab.pdf [Accessed 2009 Mar 18]
75. US Factive- package insert [online]. Available from URL: http://www.factive.com/pdf/prescribing-info.pdf [Accessed 2009 Mar 18]
76. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001 Oct; 35 (10): 1194-8
77. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999 Feb; 28 (2): 352-64
78. Lode H. Potential interactions of the extended-spectrum fluoroquinolones with the CNS. Drug Saf 1999 Aug; 21 (2): 123-35
79. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001 Oct; 21 (10 Pt 2): 253-72S
80. Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999 Nov; 21 (5): 407-21
81. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998 Jul; 42 (7): 1831-6
82. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008 Aug; 154 (7): 1502-7
83. Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002 Jul; 302 (1): 320-7
84. Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006 Dec 15; 43 (12): 1603-11
85. + channel HERG. Mol Pharmacol 2001 Jan; 59 (1): 122-6
86. Alexandrou AJ, Duncan RS, Sullivan A, et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 2006 Apr; 147 (8): 905-16
87. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007 Apr; 29 (4): 374-9
88. Brown AM. Drugs hERG and sudden death. Cell Calcium 2004 Jun; 35 (6): 543-7
89. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001 Dec; 21 (12): 1468-72
90. Poluzzi E, Raschi E, Moretti U, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. Epub 2009 Apr 8
91. Shaffer DN. Macrolide antibiotics and torsade de pointes: postmarketing analysis [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/ slides/3746s-02-shaffer.ppt [Accessed 2008 Jul 23]
92. US Food and Drug Administration. Adverse event reporting system (AERS) [online]. Available from URL: http://www.fda.gov/cder/aers/default.htm [Accessed 2009 Mar 18]
93. US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program [online]. Available from URL: www.fda.gov/medwatch [Accessed 2009 Mar 18]
94. Veyssier P, Voirot P, Begaud B, et al. Cardiac tolerance of moxifloxacin: clinical experience froma large observational French study in usual medical practice (IMMEDIAT study) [in French]. Med Mal Infect 2006 Oct; 36 (10): 505-12
95. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 Mar 4; 350 (10): 1013-22
96. Owens Jr RC. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004; 64 (10): 1091-124
97. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000 Oct; 50 (4): 285-95
98. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006 Apr; 7 (6): 639-51
99. Simkó J, Csilek A, Kará szi J, et al. Proarrhythmic potential of antimicrobial agents. Infection 2008; 36: 194-206
100. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003 May; 51 Suppl. 1: 21-7
101. Dale KM, Lertsburapa K, Kluger J, et al. Moxifloxacin and torsade de pointes. Ann Pharmacother 2007 Feb; 41 (2): 336-40
102. Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with communityacquired pneumonia. The MOTIV study: a randomized clinical trial. Clin Infect Dis 2008May 15; 46 (10): 1499-509
103. Chen X, Cass JD, Bradley JA, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005 Nov; 146 (6): 792-9
104. Barth J, Jä gerD,MundkowskiR, et al. Single- and multipledose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J Antimicrob Chemother 2008 Sep; 62(3): 575-8
105. Voss MA Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability. Br J Pharmacol 2008; 154: 1523-7
106. Wisialowski T, Crimin K, Engtrakul J, et al. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006 Jul; 318 (1): 352-9
107. Andrade RJ, Lucena MI, Fernandez MC, et al. Druginduced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005 Aug; 129 (2): 512-21
108. De Valle MB, Av KV, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006 Oct 15; 24 (8): 1187-95
109. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007 Jun 15; 25 (12): 1411-21
110. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006 Dec; 44 (6): 1581-8
111. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005 Aug; 42 (2): 481-9
112. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007 May 15; 25 (10): 1135-51
113. Robles M, Andrade RJ. Antibiotic induced hepatotoxicity: 2008 update. in Spanish. Rev Esp Quimioter 2008 Dec; 21 (4): 224-33
114. Andrade RJ, Robles M, Fernandez-Castaner A, et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007 Jan 21; 13 (3): 329-40
115. Lucena MI, Garcia-Cortes M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008 Apr; 22 (2): 141-58
116. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006 May; 10 (2): 207-17, vii
117. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 2004 Feb; 8 (1): 83-94
118. Pessayre D, Larrey D, Funck-Brentano C, et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985 Jul; 16 Suppl. A: 181-94
119. Freneaux E, Labbe G, Letteron P, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988 Sep; 8 (5): 1056-62
120. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994 Jun; 18 (6): 946-50
121. Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000 Feb 3; 342 (5): 359-60
122. Lucena MI, Andrade RJ, Rodrigo L, et al. Trovafloxacininduced acute hepatitis. Clin Infect Dis 2000 Feb; 30 (2): 400-1
123. Sun Q, Zhu R, Foss FW, et al. In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. Chem Res Toxicol 2008 Mar; 21 (3): 711-9
124. Shaw PJ, Ditewig AC, Waring JF, et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci 2009 Jan; 107 (1): 270-80
125. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990 Sep; 11 (2): 272-6
126. Sabate M, Ibanez L, Perez E, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007 Jun 15; 25 (12): 1401-9
127. Galan MV, Potts JA, Silverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol 2005 Jan; 39 (1): 64-7
128. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006 Jan; 38 (1): 33-8
129. Sgro C, Clinard F, Ouazir K, et al. Incidence of druginduced hepatic injuries: a French population-based study. Hepatology 2002 Aug; 36 (2): 451-5
130. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004 Jul; 58 (1): 71-80
131. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996 Jun 24; 156 (12): 1327-32
132. Perez GS, Garcia Rodriguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993 Nov; 4 (6): 496-501
133. Rullo B. Hepatic safety experience [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1-02-07-%20Ketek-Rullo. pdf [Accessed 2008 Jul 7]
134. Brinker A. Telithromycin-associated hepatotoxicity [online]. Available from URL: http://www.fda.gov/ohrms/dockets/AC/06/slides/2006-4266s1-01-07-FDA- Brinker.ppt [Accessed 2008 Jul 7]
135. US Augmentin® package insert [online]. Available from URL: http://us.gsk.com/products/assets/us-augmentin.pdf [Accessed 2008 Jul 7]
136. Karim A, Ahmed S, Rossoff LJ, et al. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis 2001 Dec 15; 33 (12): 2088-90
137. Coban S, Ceydilek B, Ekiz F, et al. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. Ann Pharmacother 2005 Oct; 39 (10): 1737-40
138. Schwalm JD, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ 2003 Apr 1; 168 (7): 847-8
139. Soto S, Lopez-Roses L, Avila S, et al. Moxifloxacininduced acute liver injury. Am J Gastroenterol 2002 Jul; 97 (7): 1853-4
140. Electronic Medicines Compendium (eMC). Summary of product characteristics: Avelox 400 mg tablets [online]. Available from URL: http://emc.medicines.org.uk/medicine/11841/SPC/Avelox+400+mg+Tablets/ [Accessed 2009 Mar 31]
141. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996 Jan; 117 (2): 372-6
142. Lewis RJ, Mohr III JF. Dysglycaemias and fluoroquinolones. Drug Saf 2008; 31 (4): 283-92
143. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003 Aug 11; 163 (15): 1825-9
144. Owens Jr RC. Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy 2005Oct; 25 (10): 1291-5
145. Shilo S, Berezovsky S, Friedlander Y, et al. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc 1998 Aug; 46 (8): 978-82
146. Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005 Oct; 25 (10): 1303-9
147. Graumlich JF, Habis S, Avelino RR, Gaynes RP, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005 Oct; 25 (10): 1296-302
148. Owens Jr RC, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008 Jan 15; 46 Suppl. 1: S19-31
149. McFarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for Clostridium difficile associated disease within a Veterans Administration health care system. Clin Infect Dis 2007 Nov 1; 45 (9): 1141-51
150. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 Nov 1; 41 (9): 1254-60
151. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004 Mar 1; 38 (5): 640-5
152. Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006 Sep; 50 (9): 3216-9
153. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007 Feb; 28 (2): 198-201
154. Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009 Feb; 63 (2): 238-42
155. Generali J. Black box warnings from the FDA [online]. Available from URL: http://www.formularyproductions.com/blackbox/ [Accessed 2008 Jul 9]
156. US Ceftin® package insert [online]. Available from URL: http://us.gsk.com/products/assets/us-ceftintablets.pdf [Accessed 2008 Jul 9]
157. US Biaxin® package insert [online]. Available from URL: http://www.rxabbott.com/pdf/biapi.pdf [Accessed 2008 Jul 9]
158. US Zithromax® package insert [online]. Available from URL: http://media.pfizer.com/files/products/uspi-zithromax.pdf [Accessed 2008 Jul 9]
159. US Ketek® package insert [online]. Available from URL: http://products.sanofi-aventis.us/ketek/Ketek.pdf [Accessed 2008 Jul 9]
160. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin 2007 Jun; 23 (6): 1403-13
161. Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006 Apr; 61 (4): 337-42
162. Keating KN, Friedman HS, Perfetto EM. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges. Curr Med Res Opin 2006 Feb; 22 (2): 327-33
163. Simoens S, Decramer M, Laekeman G, et al. Respir Med 2007 Jan; 101 (1): 15-26
164. Llor C, Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract 2004 Oct; 58 (10): 937-44
165. Martin M, Moore L, Quilici S, et al. A cost-effectiveness analysis of antimicrobial treatment of communityacquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin 2008 Mar; 24 (3): 737-51
166. Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in communityacquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007 May; 59 (5): 977-89
167. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003 Aug; 124 (2): 526-35
168. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005 Oct; 128 (4): 2238-46
169. Davis SL, Delgado Jr G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005 Jul 15; 41 Suppl. 2: S136-43
170. Simoens S, Decramer M. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert Opin Pharmacother 2008 Jul; 9 (10): 1735-44